Qantas confirms personal data of over a million customers leaked in breach
The airline operator said that another four million customers had just their name and email address taken during the hack.
After disclosing a cyberattack last week, Qantas said on Wednesday that the breached database contained unique personal information of 5.7 million customers, after removing duplicate records from the initial 6 million affected.
There is no evidence that any personal data of the customers has been released and the company is actively monitoring the situation, Qantas said in a statement.
"Since the incident, we have put in place a number of additional cyber security measures to further protect our customers' data, and are continuing to review what happened," Qantas Group CEO Vanessa Hudson said.
The breach represents Australia's most high-profile cyber attack since telecommunications giant Optus and health insurer Medibank were hit in 2022, incidents that prompted mandatory cyber resilience laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
36 minutes ago
- TechCrunch
Hacker used a voice phishing attack to steal Cisco customers' personal information
A cybercriminal tricked a Cisco representative into granting them access to steal the personal information of users, the company said on Tuesday. Cisco said it discovered the breach on July 24, blaming the incident on a voice phishing or 'vishing' call. The hackers accessed and exported 'a subset of basic profile information' from the database of a third party cloud-based customer relationship management (CRM) system, according to the company's disclosure. Cisco said that the stolen data included the customer's 'name, organization name, address, Cisco assigned user ID, email address, phone number, and account-related metadata,' such as the account creation date. The networking tech giant did not specify how many users were affected by the breach, and company spokespeople did not respond to that question when TechCrunch reached out on Tuesday. As Bleeping Computer noted, this breach could be another one in a string of attacks that targeted companies' Salesforce data, including U.S. insurance giant Allianz Life, luxury retailer Tiffany and Co., Australian airline Qantas, and others. Cisco is a known customer of Salesforce, according to the cloud giant.
Yahoo
41 minutes ago
- Yahoo
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ('efti'), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating efti in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab), the FDA agreed on the potential of efti in combination with KEYTRUDA to address the high unmet need in this CPS <1 patient segment and is supportive of the combination's further development. Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data. 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,' said Marc Voigt, CEO of Immutep. 'Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer,' added Mr Voigt. Project FrontRunner is an FDA Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to develop and seek approval of cancer drugs for advanced/metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients' lives. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy's progress in fighting cancer, anti-PD-1 therapy alone (without chemotherapy) is only approved for patients who express PD-L1 (CPS >1). All currently available treatment options for patients with PD-L1 CPS <1 include chemotherapy. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
Yahoo
an hour ago
- Yahoo
Analysis-Easy to lose, hard to restore: US data trust on the line
By Andrea Shalal and Davide Barbuscia WASHINGTON/NEW YORK (Reuters) -Donald Trump's move to fire the head of the U.S. Bureau of Labor Statistics has put trust in U.S. data reporting mechanisms on the line just as demand for reliable diagnoses of the health of the world's largest economy is bigger than ever. Examples from elsewhere show credibility is easily lost and hard to restore. A first test will be the choice to replace Erika McEntarfer, accused without evidence by Trump of manipulating U.S. job numbers after weaker-than-expected growth and large downward revisions were reported last week. "Imagine if one of your concerns is that there's a lackey in charge of the agency and the numbers are fake," said Michael Strain, director of economic policy studies at the conservative American Enterprise Institute, of an appointment Trump has said to expect within days. "That's a whole other level of problems." Policymakers, businesses and investors are scrambling to understand how Trump's attempt to up-end the global trade system will affect prices, employment and household wealth. Central banks, which once tried to guide market bets on rate moves months down the line, now say decisions are "data-dependent." The rub is that data collection is proving to be harder. Debt-laden governments have, as McEntarfer experienced, cut resources in their data departments; phone surveys, the go-to method for much macro research, are struggling to produce adequate samples as many households do without fixed lines. Trump's implicit accusation of partisanship by "this Biden Political Appointee" adds the troubling factor of a political dimension usually indicative of countries dogged by wider doubts over their democratic checks and balances. The key lesson from past examples of loss of data confidence is that it can take years for trust to be restored. 'MAN-MADE' NUMBERS When Argentina last year reported its first single-digit inflation in months, sceptics questioned the data and recalled the massive underreporting of inflation in the 2000s and 2010s for which it was censured by the International Monetary Fund. "They manipulated the data for a long time," said Aldo Abram of libertarian think tank Liberty and Progress Foundation in Buenos Aires. "It's logical people remember this and continue having doubts." Turkey has changed the head of its TUIK statistics institute four times since 2019, with opposition parties arguing the changes were political. Roger Marks, fixed income analyst at asset manager Ninety One, said the result for investors has been a "gradual erosion of our trust in the numbers." For Greece, whose efforts during the 2000s to conceal mounting public deficits fed that decade's sovereign debt crisis, it has been an equally long haul back to credibility. It required the overhaul of its ELSTAT statistics agency in 2016 and the creation of an international panel of experts to appoint its chief statistician - steps that have meant its hard-fought efforts to improve its budget are now unquestioned. It also prompted European governments to grant the Eurostat statistics arm of the European Union powers to check suspect national statistics reported to it. Longstanding doubts over the accuracy of Chinese statistics - with even former Premier Li Keqiang acknowledging in 2007 the country's output figures were man-made - have obscured genuine efforts to improve data quality, such as a new measure of youth unemployment excluding students that was released early in 2024. "There were genuine methodological reasons for the change, but because of the history around Chinese data a lot of people, particularly foreign investors, just didn't really trust that," Julian Evans-Pritchard, an analyst with Capital Economics. "That underscores to me that once you undermine confidence in the data, it is quite hard to restore that confidence." SPOILS SYSTEM Faced over the years with patchy official data, watchers of emerging economies have long sought to corroborate those numbers with other datasets. Capital Economics' China Activity Proxy is based on 18 indicators from freight traffic to electricity consumption. Another metric is found in the data and sentiment surveys provided by independent researchers in all the big economies. But they can only sketch in one perspective on the picture. "An awful lot of it is soft data: 'How do you feel? What do you think's going on?'" said Erik Weisman, chief economist and portfolio manager at MFS Investment Management in Boston. "They're not asking for specifics. They're not asking, how many widgets did you produce? How many insurance policies did you produce? How many hours worked?," he said, adding that the concerns raised by the sacking of McEntarfer could nonetheless force analysts to turn increasingly to those other sources. The most urgent question now is whether the breach in credibility which the Trump intervention has opened is now widened further or mended. Enrico Giovannini, former chief statistician for the Paris-based Organisation for Economic Co-operation and Development (OECD), said there was more scope in the U.S. for political appointments of key statistics roles than in other advanced economies which tended to make long, fixed-term appointments. "So the incoming government has to wait (to replace them), said Giovannini, who has also served in two Italian governments. "In the U.S., the spoils system works," he said of the practice of party supporters getting rewarded with government jobs. The International Statistical Institute, a professional organization for data collectors, issued a statement late on Monday that said Trump's move violated U.N. principles aimed at protecting fact-based statistics and called on his government to take steps to restore public confidence in U.S. federal data. William Wiatrowski, the BLS' deputy commissioner, will serve as acting commissioner until a successor to McEntarfer is named. Beyond that choice, some fear that further dangers may emerge from a Trump executive order on federal hiring intended to reserve posts for candidates who can prove they are "dedicated to the furtherance of American ideals, values, and interests." Aaron Sojourner, a senior researcher at the W.E. Upjohn Institute for Employment Research, said such a move would, if passed by Congress, apply to many jobs in federal economic statistical agencies. "This proposal would convert many of those jobs into political jobs where people can be fired for any reason if they displease a political leader," Sojourner said. (Writing by Mark John; additional reporting by Claire Fu in Singapore, Marius Zaharia in Hong Kong, Karin Strohecker in London, David Lawder in Washington, Leila Miller in Buenos Aires; Lefteris Papadimas in Athens, Indradip Ghosh and Sarupya Ganguly in Bengaluru; editing by Paul Simao) Sign in to access your portfolio
